Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jan 06, 2023 12:39pm

169 Views

Post# 35207184

OV company Transgene begins Phase I trial for IV delivery

The Transgene Phase I trial, named Delivir, will evaluate the intravenous (IV) administration of their OV TG6050 in patients with non-small cell lung cancer.

https://www.biospace.com/article/releases/transgene-receives-approval-to-start-a-phase-i-trial-of-tg6050-a-novel-il-12-armed-oncolytic-virus-given-by-intravenous-administration/

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing